减轻囊性纤维化的治疗负担：过度简化治疗方法是否存在风险？ - Suppr

Reducing Treatment Burden in Cystic Fibrosis: Is There a Risk to OverSIMPLIFYing Therapies?

作者信息

Quon Bradley S

机构信息

Division of Respiratory Medicine, Department of Medicine, and.

Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

出版信息

Ann Am Thorac Soc. 2024 Nov;21(11):1483-1484. doi: 10.1513/AnnalsATS.202407-694ED.

DOI:10.1513/AnnalsATS.202407-694ED

PMID:39485168

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11568499/

Abstract

摘要

相似文献

Reducing Treatment Burden in Cystic Fibrosis: Is There a Risk to OverSIMPLIFYing Therapies?减轻囊性纤维化的治疗负担：过度简化治疗方法是否存在风险？

Ann Am Thorac Soc. 2024 Nov;21(11):1483-1484. doi: 10.1513/AnnalsATS.202407-694ED.

Future therapies for cystic fibrosis.囊性纤维化的未来疗法。

Nat Commun. 2023 Feb 8;14(1):693. doi: 10.1038/s41467-023-36244-2.

Epidemiology of advanced cystic fibrosis lung disease in the modulator era.调节剂时代晚期囊性纤维化肺病的流行病学

Curr Opin Pulm Med. 2024 Nov 1;30(6):633-639. doi: 10.1097/MCP.0000000000001115. Epub 2024 Aug 22.

Recent advances in the management of cystic fibrosis.囊性纤维化治疗的最新进展

Arch Dis Child. 2014 Nov;99(11):1033-6. doi: 10.1136/archdischild-2013-304400. Epub 2014 Jul 4.

Using Cystic Fibrosis Therapies for Non-Cystic Fibrosis Bronchiectasis.将囊性纤维化治疗方法用于非囊性纤维化支气管扩张症。

Clin Chest Med. 2016 Mar;37(1):139-46. doi: 10.1016/j.ccm.2015.11.005. Epub 2015 Dec 23.

AR-13 reduces antibiotic-resistant bacterial burden in cystic fibrosis phagocytes and improves cystic fibrosis transmembrane conductance regulator function.AR-13 降低了囊性纤维化吞噬细胞中的抗生素耐药菌负荷，并改善了囊性纤维化跨膜电导调节因子的功能。

J Cyst Fibros. 2019 Sep;18(5):622-629. doi: 10.1016/j.jcf.2018.10.010. Epub 2018 Oct 23.

Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor combination: a 1-year observational study.囊性纤维化患者使用依利卓艾卡托替卡那三联组合治疗的呼吸物理治疗感知负担：一项为期 1 年的观察性研究。

Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241235054. doi: 10.1177/17534666241235054.

Nutritional and metabolic management for cystic fibrosis in a post-cystic fibrosis transmembrane conductance modulator era.囊性纤维化跨膜电导调节因子后时代的囊性纤维化的营养和代谢管理。

Curr Opin Pulm Med. 2022 Nov 1;28(6):577-583. doi: 10.1097/MCP.0000000000000917. Epub 2022 Sep 14.

Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population.调节剂难治性囊性纤维化：定义一个新兴高危人群的范围和挑战。

Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241297877. doi: 10.1177/17534666241297877.

Treatment of pulmonary exacerbations in cystic fibrosis.囊性纤维化肺部感染的治疗。

Curr Opin Pulm Med. 2020 Nov;26(6):679-684. doi: 10.1097/MCP.0000000000000730.

本文引用的文献

Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.停止使用 Elexacaftor-Tezacaftor-Ivacaftor 后，高渗盐水和脱氧核糖核酸酶 α 对囊性纤维化的影响。

Ann Am Thorac Soc. 2024 Nov;21(11):1507-1515. doi: 10.1513/AnnalsATS.202404-366OC.

Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor.依列卡福妥/替扎卡福妥/依伐卡托治疗开始后的药物使用情况及肺功能变化

Pediatr Pulmonol. 2024 Jul;59(7):2051-2054. doi: 10.1002/ppul.27018. Epub 2024 Apr 17.

The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study.依洛尤单抗治疗成人原发性高胆固醇血症的疗效和安全性：一项多中心、随机、双盲、安慰剂对照研究

J Cyst Fibros. 2024 May;23(3):457-460. doi: 10.1016/j.jcf.2024.02.003. Epub 2024 Feb 13.

Standards for the care of people with cystic fibrosis; establishing and maintaining health.囊性纤维化患者护理标准；建立和维护健康。

J Cyst Fibros. 2024 Jan;23(1):12-28. doi: 10.1016/j.jcf.2023.12.002. Epub 2023 Dec 21.

Assessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.评估在接受依列卡福妥/替扎卡福妥/依伐卡福妥治疗后一秒用力呼气量较低的患者中停用高渗盐水的安全性。

Ann Am Thorac Soc. 2024 Feb;21(2):360-362. doi: 10.1513/AnnalsATS.202308-735RL.

Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation.在开始使用 elexacaftor/tezacaftor/ivacaftor 之前和之后使用囊性纤维化吸入药物。

J Cyst Fibros. 2024 Jan;23(1):29-31. doi: 10.1016/j.jcf.2023.05.001. Epub 2023 May 9.

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.调制治疗的囊性纤维化患者中停用或继续使用高渗盐水或脱氧核糖核酸酶 α（SIMPLIFY）：两项平行、多中心、开放标签、随机、对照、非劣效性试验的结果。

Lancet Respir Med. 2023 Apr;11(4):329-340. doi: 10.1016/S2213-2600(22)00434-9. Epub 2022 Nov 4.

Research letter: The impact of elexacaftor/tezacaftor/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis.研究信函：依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化患者雾化维持治疗依从性的影响

J Cyst Fibros. 2022 Nov;21(6):1080-1081. doi: 10.1016/j.jcf.2022.05.005. Epub 2022 May 16.

Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design.评估囊性纤维化调制药物治疗后停止慢性治疗的影响：SIMPLIFY 临床试验研究设计。

Ann Am Thorac Soc. 2021 Aug;18(8):1397-1405. doi: 10.1513/AnnalsATS.202010-1336SD.

Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy.响应号召，在高效 CFTR 调节剂治疗时代解决囊性纤维化治疗负担问题。

J Cyst Fibros. 2020 Sep;19(5):762-767. doi: 10.1016/j.jcf.2019.11.007. Epub 2019 Nov 21.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reducing Treatment Burden in Cystic Fibrosis: Is There a Risk to OverSIMPLIFYing Therapies?

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献